66
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A critical question in tuberculosis control is why some strains of Mycobacterium tuberculosis are preferentially associated with multiple drug resistances. We demonstrate that M. tuberculosis strains from Lineage 2 (East Asian lineage and Beijing sublineage) acquire drug resistances in vitro more rapidly than M. tuberculosis strains from Lineage 4 (Euro-American lineage) and that this higher rate can be attributed to a higher mutation rate. Moreover, the in vitro mutation rate correlates well with the bacterial mutation rate in humans as determined by whole genome sequencing of clinical isolates. Finally, using a stochastic mathematical model, we demonstrate that the observed differences in mutation rate predict a substantially higher probability that patients infected with a drug susceptible Lineage 2 strain will harbor multidrug resistant bacteria at the time of diagnosis. These data suggest that interventions to prevent the emergence of drug resistant tuberculosis should target bacterial as well as treatment-related risk factors.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

          Although progress has been made to reduce global incidence of drug-susceptible tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis during the past decade threatens to undermine these advances. However, countries are responding far too slowly. Of the estimated 440,000 cases of MDR tuberculosis that occurred in 2008, only 7% were identified and reported to WHO. Of these cases, only a fifth were treated according to WHO standards. Although treatment of MDR and XDR tuberculosis is possible with currently available diagnostic techniques and drugs, the treatment course is substantially more costly and laborious than for drug-susceptible tuberculosis, with higher rates of treatment failure and mortality. Nonetheless, a few countries provide examples of how existing technologies can be used to reverse the epidemic of MDR tuberculosis within a decade. Major improvements in laboratory capacity, infection control, performance of tuberculosis control programmes, and treatment regimens for both drug-susceptible and drug-resistant disease will be needed, together with a massive scale-up in diagnosis and treatment of MDR and XDR tuberculosis to prevent drug-resistant strains from becoming the dominant form of tuberculosis. New diagnostic tests and drugs are likely to become available during the next few years and should accelerate control of MDR and XDR tuberculosis. Equally important, especially in the highest-burden countries of India, China, and Russia, will be a commitment to tuberculosis control including improvements in national policies and health systems that remove financial barriers to treatment, encourage rational drug use, and create the infrastructure necessary to manage MDR tuberculosis on a national scale. Copyright 2010 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

            Mathematical models predict that the future of the multidrug-resistant tuberculosis epidemic will depend on the fitness cost of drug resistance. We show that in laboratory-derived mutants of Mycobacterium tuberculosis, rifampin resistance is universally associated with a competitive fitness cost and that this cost is determined by the specific resistance mutation and strain genetic background. In contrast, we demonstrate that prolonged patient treatment can result in multidrug-resistant strains with no fitness defect and that strains with low- or no-cost resistance mutations are also the most frequent among clinical isolates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

              Treatment of tuberculosis, a complex granulomatous disease, requires long-term multidrug therapy to overcome tolerance, an epigenetic drug resistance that is widely attributed to nonreplicating bacterial subpopulations. Here, we deploy Mycobacterium marinum-infected zebrafish larvae for in vivo characterization of antitubercular drug activity and tolerance. We describe the existence of multidrug-tolerant organisms that arise within days of infection, are enriched in the replicating intracellular population, and are amplified and disseminated by the tuberculous granuloma. Bacterial efflux pumps that are required for intracellular growth mediate this macrophage-induced tolerance. This tolerant population also develops when Mycobacterium tuberculosis infects cultured macrophages, suggesting that it contributes to the burden of drug tolerance in human tuberculosis. Efflux pump inhibitors like verapamil reduce this tolerance. Thus, the addition of this currently approved drug or more specific efflux pump inhibitors to standard antitubercular therapy should shorten the duration of curative treatment. Copyright © 2011 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                4 September 2013
                09 June 2013
                July 2013
                01 January 2014
                : 45
                : 7
                : 784-790
                Affiliations
                [1 ]Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA
                [2 ]Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California, USA
                [3 ]Swiss Tropical & Public Health Institute, Basel, Switzerland
                [4 ] University of Basel, Basel, Switzerland
                [5 ]Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
                [6 ]Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA
                [7 ]Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
                [8 ]Communicable Disease Prevention and Control Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
                [9 ]Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada
                [10 ]Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA
                [11 ]Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
                Author notes
                Correspondence should be addressed to S.M.F. ( sfortune@ 123456hsph.harvard.edu )

                Author Contributions: C.B.F. designed the study, performed experimental and molecular studies, developed mathematical models and conducted analyses, prepared the figures and drafted the manuscript; R.S.S. performed experimental studies; M.K.M. and S.G. isolated clinical strains; M.B.M. and T.C. advised development of the mathematical model; J.C.J. and J.G. contributed to analyses; M.L. advised design of the study and data analysis, including development of the mathematical model; S.M.F. designed the study, supervised experimental and molecular studies, and drafted the manuscript. All authors edited the manuscript.

                Article
                NIHMS477333
                10.1038/ng.2656
                3777616
                23749189
                5e2af31f-5b79-4dde-90c0-4618a73369fb

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Institute of General Medical Sciences : NIGMS
                Award ID: U54 GM088558 || GM
                Funded by: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID
                Award ID: U19 AI076217 || AI
                Funded by: Office of the Director : NIH
                Award ID: DP2 OD001378 || OD
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article